We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aptamer

News List

Aptamer and WuXi AppTec Form Research Partnership contractpharma
July 23, 2021
Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, have entered a research collaboration to identify new Optimer-enabled therapeutics.
Aptamer Group Collaborates with PinotBio contractpharma
June 03, 2021
Aptamer Group Limited, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for ...
Aptamer Extends Collaboration with AstraZeneca contractpharma
March 08, 2021
Aptamer Group, the developer of Optimer reagents and therapeutics, has extended their current agreement with AstraZeneca.
Aptamer Group, AstraZeneca extend collaboration to explore next-gen drug delivery approaches expresspharma
March 05, 2021
The companies will evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.